JPWO2021183873A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021183873A5 JPWO2021183873A5 JP2022554769A JP2022554769A JPWO2021183873A5 JP WO2021183873 A5 JPWO2021183873 A5 JP WO2021183873A5 JP 2022554769 A JP2022554769 A JP 2022554769A JP 2022554769 A JP2022554769 A JP 2022554769A JP WO2021183873 A5 JPWO2021183873 A5 JP WO2021183873A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- thio
- pharmaceutical composition
- inhibitor
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989041P | 2020-03-13 | 2020-03-13 | |
| US62/989,041 | 2020-03-13 | ||
| PCT/US2021/022090 WO2021183873A1 (en) | 2020-03-13 | 2021-03-12 | Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023517671A JP2023517671A (ja) | 2023-04-26 |
| JP2023517671A5 JP2023517671A5 (https=) | 2024-03-05 |
| JPWO2021183873A5 true JPWO2021183873A5 (https=) | 2024-03-05 |
| JP7829491B2 JP7829491B2 (ja) | 2026-03-13 |
Family
ID=77671975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554769A Active JP7829491B2 (ja) | 2020-03-13 | 2021-03-12 | ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12097213B2 (https=) |
| EP (1) | EP4117667B1 (https=) |
| JP (1) | JP7829491B2 (https=) |
| KR (1) | KR20220154134A (https=) |
| CN (1) | CN115397428A (https=) |
| AU (1) | AU2021233023B2 (https=) |
| BR (1) | BR112022018238A2 (https=) |
| CA (1) | CA3170930A1 (https=) |
| DK (1) | DK4117667T3 (https=) |
| ES (1) | ES3014683T3 (https=) |
| FI (1) | FI4117667T3 (https=) |
| HU (1) | HUE070513T2 (https=) |
| IL (1) | IL296403A (https=) |
| MX (1) | MX2022011331A (https=) |
| PL (1) | PL4117667T3 (https=) |
| PT (1) | PT4117667T (https=) |
| WO (1) | WO2021183873A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019183482A1 (en) | 2018-03-22 | 2019-09-26 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS |
| WO2025090539A1 (en) * | 2023-10-22 | 2025-05-01 | Regeneron Pharmaceuticals, Inc. | Treatment of non-small cell lung cancer with 6-thio-dg and cemiplimab |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012052181A1 (en) * | 2010-10-22 | 2012-04-26 | Roche Diagnostics Gmbh | A conjugate between a thiophilic solid phase and an oligonucleotide comprising a thiooxonucleotide |
| CA2907924C (en) | 2013-04-08 | 2022-10-25 | The Board Of Regents Of The University Of Texas System | Telomerase mediated telomere altering compounds |
| CN116059219A (zh) * | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
| US20180036331A1 (en) | 2016-03-24 | 2018-02-08 | The Board Of Regents Of The University Of Texas System | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds |
| EP3463370A4 (en) * | 2016-05-27 | 2020-04-08 | The Board of Regents of The University of Texas System | 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE-DEPENDENT TELOMER DYS FUNCTION AND CELL DEATH IN THERAPY-RESISTANT CANCER CELL |
| KR20190053909A (ko) | 2016-09-16 | 2019-05-20 | 바이오노믹스 리미티드 | 항체와 체크포인트 면역 억제제의 병용 요법 |
| KR20240011262A (ko) * | 2017-02-21 | 2024-01-25 | 리제너론 파아마슈티컬스, 인크. | 폐암의 치료를 위한 항-pd-1 항체 |
| JP2020515637A (ja) | 2017-04-03 | 2020-05-28 | オンコロジー、インコーポレイテッド | 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法 |
| WO2019152574A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
| US20210113602A1 (en) | 2018-02-28 | 2021-04-22 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-2'-DEOXYGUANOSINE (6-THIO-dG) TO TREAT MELANOMA |
| WO2019183482A1 (en) * | 2018-03-22 | 2019-09-26 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS |
-
2021
- 2021-03-12 BR BR112022018238A patent/BR112022018238A2/pt unknown
- 2021-03-12 HU HUE21767125A patent/HUE070513T2/hu unknown
- 2021-03-12 JP JP2022554769A patent/JP7829491B2/ja active Active
- 2021-03-12 PL PL21767125.4T patent/PL4117667T3/pl unknown
- 2021-03-12 FI FIEP21767125.4T patent/FI4117667T3/fi active
- 2021-03-12 IL IL296403A patent/IL296403A/en unknown
- 2021-03-12 DK DK21767125.4T patent/DK4117667T3/da active
- 2021-03-12 MX MX2022011331A patent/MX2022011331A/es unknown
- 2021-03-12 PT PT217671254T patent/PT4117667T/pt unknown
- 2021-03-12 US US17/200,539 patent/US12097213B2/en active Active
- 2021-03-12 CN CN202180028952.2A patent/CN115397428A/zh active Pending
- 2021-03-12 AU AU2021233023A patent/AU2021233023B2/en active Active
- 2021-03-12 KR KR1020227033906A patent/KR20220154134A/ko active Pending
- 2021-03-12 CA CA3170930A patent/CA3170930A1/en active Pending
- 2021-03-12 EP EP21767125.4A patent/EP4117667B1/en active Active
- 2021-03-12 ES ES21767125T patent/ES3014683T3/es active Active
- 2021-03-12 WO PCT/US2021/022090 patent/WO2021183873A1/en not_active Ceased
-
2024
- 2024-09-09 US US18/829,162 patent/US20240424013A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007523862A5 (https=) | ||
| Nishimura | Rationale for chemoradiotherapy | |
| JP2021063120A5 (https=) | ||
| Horiotº et al. | European Organization for Research on Treatment of Cancer Trials Using Radiotherapy | |
| CY1109607T1 (el) | Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2022269525A5 (https=) | ||
| JP2009506054A5 (https=) | ||
| JP2022500479A5 (https=) | ||
| Li et al. | Exploring hypoxic biology to improve radiotherapy outcomes | |
| US6281223B1 (en) | Radioenhanced camptothecin derivative cancer treatments | |
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| EP3960243A1 (en) | Pharmaceutical composition for preventing or treating treatment-resistant cancer | |
| FI4117667T3 (fi) | Syöpien jaksottainen hoito käyttäen 6-tio-dg- ja tarkistuspisteen inhibiittoreita | |
| JPWO2021183873A5 (https=) | ||
| CN117083086A (zh) | 腺苷二磷酸核糖在放射和／或抗癌治疗辅助疗法中的应用 | |
| JP2006528696A (ja) | 抗癌剤の抗腫瘍活性を増強する方法 | |
| JP2018511642A5 (https=) | ||
| JPH1045589A (ja) | テモゾロミドによる改良されたガンの処置 | |
| ES3010436T3 (en) | Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient | |
| CN101175495B (zh) | 抗癌化合物的组合 | |
| CN112741833A (zh) | 西达本胺及其衍生物的用途 | |
| JPWO2023078881A5 (https=) | ||
| Liu et al. | Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR Tcell therapy in aggressive mantle cell lymphoma | |
| JP7684719B2 (ja) | 腫瘍に対する免疫を賦活させるための医薬組成物及びその方法 |